When Dr. Beata Halassy learned in 2020 that her breast cancer had returned for the third time, she faced a choice that almost no one else on earth could have made. A virologist at the University of Zagreb in Croatia, she had spent her career growing and studying viruses in the laboratory, and after two previous rounds of surgery and chemotherapy, she decided to try something that had never been done: treating her own tumor by injecting viruses she cultivated herself, using a measles vaccine strain and a second virus administered directly into the tumor over two months while her oncologists monitored her closely and stood ready to switch to conventional treatment if anything went wrong. What unfolded over those weeks stunned everyone watching, as the tumor shrank, softened, and detached from the surrounding tissue, making surgical removal far less invasive than it would have been without the treatment.
When the tissue was analyzed after surgery, it was flooded with immune cells that had finally learned to recognize and target the cancer after the viral injections had essentially lit it up for the immune system to see. Halassy has been entirely cancer-free for four years, and her case was eventually published in the journal Vaccines after more than a dozen rejections from publications uncomfortable with the ethics of self-experimentation. Her story has electrified the cancer research community not because doctors recommend replicating what she did, but because it offers a rare and vivid window into the potential of oncolytic virotherapy, an approach that uses carefully chosen viruses to turn cold, immune-invisible tumors into ones the body can finally fight. Researchers around the world are now actively racing to develop this field, and Halassy’s extraordinary case is part of what is pushing them forward.
